Sanofi-Aventis (Suisse) SA - Revaxis, suspension injectable | | 00646 | | 01 | | Revaxis | | suspension injectable | | J07CA01 | | Diphtheria-Poliomyelitis-Tetanus | | 10.08.2000 | | |
| Composition | toxoidum tetani min. 20 U.I., toxoidum diphtheriae min. 2 U.I., virus poliomyelitis typus 1 inactivatus 29 U., virus poliomyelitis typus 2 inactivatus 7 U., virus poliomyelitis typus 3 inactivatus 26 U., aluminium 0.35 mg ut aluminii hydroxidum hydricum ad adsorptionem, formaldehydum, medium 199 cum phenylalaninum 12.5 µg, phenoxyethanolum, ethanolum anhydricum 2 mg, acidum hydrochloridum, natrii hydroxidum, acidum aceticum, aqua ad iniectabile, ad suspensionem pro 0.5 ml corresp., kalium 0.12 mg et natrium 1.6 mg, residui: neomycinum, streptomycinum, polymyxinum B. | Packungsbestandteile | | Injection suspension | | | | | | Active Agent | Dose |
---|
Toxoidum Diphtheriae | 2U.I. / 0.5ml | Toxoidum Tetani | 20U.I. / 0.5ml |
| BAG: Active Agent | Dose |
---|
Toxoidum Diphtheriae | 2 UI | Toxoidum Tetani | 20 UI | Vaccinum Poliomyelitidis Inactivatum (Salk typ I, II, III) | 62 U |
| | Inactive agents | Dose |
---|
Acetic Acid | | Acidum Hydrochloridum | | Alumine | 0.35mg / 0.5ml | Cum Phenylalaninum | 12.5µg / 0.5ml | Ethanol Anhydrate | 2mg / 0.5ml | Formaldehydum | | Inactivatus | 26U. / 0.5ml | Medium | 199 | Sodium Hydroxide | | Phenoxyethanol | | Virus Poliomyelitis Typus | 3 |
| |
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
---|
003 | | 11.86 | 29.30 | B | SL | No | 004 | 10 | PR | PR | B | | No |
|
|